About Us

Genzum is a globally integrated pharmaceutical product development and out-licensing company. Led by a team of industry experts, we focus on developing high barrier and complex generic pharmaceutical products for our patients around the world. Collectively, our pipeline addresses over a billion dollars of annual branded drugs sales and our product lines have been in-licensed by leading multi-billion dollar pharmaceutical companies around the world; decreasing costs, creating market value and improving the lives of many.

parallax layerparallax layer

OUR FOCUS

We cover a broad range of pharmaceutical dosage forms and have a core focus in the areas of Topical and Sterile formulations. Genzum delivers turnkey solutions to our commercial partners from product identification, product development formulation, tech-transfer, manufacturing and clinical phase III studies. We complete our focus with product licensing and product commercialization with industry-leading marketing and distribution partners. Our competitive advantage lies in our experience with difficult to develop drugs and challenging clinical designs. We co-invest with our pharmaceutical partners bringing to market often overlooked product lines and 1st to market products.

parallax layerparallax layerparallax layerparallax layer

DEVELOPMENT & LICENSING

We strive to build a dependable network of partners and commercial distributors around the world to support our overall product development life cycle. Genzum actively seeks global partnerships in the field of co-development, formulation, manufacturing, API supply and product marketing. We set our collaboration standards high in order to be the benchmark in quality, regulatory compliance and dependable on-time delivery. Our future strategy relies heavily on strategic selection of people and successful partnerships around the world. We believe that by working together, we can discover, develop, and deliver the best value for our customers.

If you have a business idea, collaboration or partnership opportunity- we want to hear from you.

: partnering@genzum.com

parallax layerparallax layer

OUR PEOPLE

Chris K. Achar
Chris K. Achar - CEO
Born in Los Angeles, CA, Chris earned his Bachelors Degree in Marketing from California State University and a Master Degree in Business from Pepperdine University School of Business.
Rajin Ahuja
Rajin Ahuja - COO
Entrepreneur & Investor in the Medical Field
Specialties: Pharmaceuticals, Drug development and licensing, FDA expertise, Consultancy
Dr. Nehru Gaddipati
Dr. Nehru Gaddipati Regulatory Affairs Advisor
30-year industry veteran with expertise in Pharmaceutical Product Development, Scale-up, Manufacturing and FDA Regulatory Affairs.
Dr.Lakshmi Raghavan
Dr.Lakshmi Raghavan R&D Scientific Advisor
Highly dynamic, goal-oriented and versatile Entrepreneur with 20+ years of pharmaceutical, drug delivery and medical device experience.
Jaimin Rajnikant Shah
Jaimin Rajnikant Shah R&D Scientific Advisor
Motivational-Innovation Leader and Team Builder. Financial Advisor-Investor, Business Planner-Incubator.
Zaidoon A. Al-Zubaidy
Zaidoon A. Al-Zubaidy Clinical Trials Advisor
Zaidoon A. Al-Zubaidy is a clinical development executive with over 25 years of experience in clinical studies (patients and healthy volunteers, Phase I–III). Zaidoon A. Al-Zubaidy is experienced in developing clinical programs for global pharmaceutical companies. He has a strong & thorough understanding of the US regulatory landscape pertaining to ANDA and the 505(b)(2) process.
parallax layerparallax layer

IN THE NEWS

Meet Us 7-10th January, 2019 at J.P. Morgan Healthcare Conference
Meet Us 9-11th October, 2018 at CPHI WorldWide 2018
IFEMA, Feria de Madrid, Madrid, Spain
Email us at partnering@genzum.com.
Read more at https://www.cphi.com/europe/
Meet Genzum at JPM Healthcare 2018
January, Union Square San Francisco – To schedule a meeting, email us at: partnering@genzum.com.

Read more at: https://www.jpmorgan.com/global/insights/healthcare

Meet Genzum at JPM Healthcare 2017
7 – 9 October 2014, Paris Nord Villepinte, France – To schedule a meeting,
Email us at partnering@genzum.com.
Read more at http://www.cphi.com/europe/about/#sthash.ppI0qBAa.dpuf
Meet Genzum at JPM Healthcare 2016
January, Union Square San Francisco – To schedule a meeting, email us at: partnering@genzum.com.

Read more at: https://www.jpmorgan.com/global/insights/healthcare

Meet Genzum at JPM Healthcare 2015
January, Union Square San Francisco – To schedule a meeting, email us at: partnering@genzum.com.

Read more at: https://www.jpmorgan.com/global/insights/healthcare

Meet Genzum at CPhI Worldwide Conference
7 – 9 October 2014, Paris Nord Villepinte, France – To schedule a meeting, email us at: partnering@genzum.com.

Read more at: http://www.cphi.com/europe/about/#sthash.ppI0qBAa.dpuf

Genzum Private Capital Raise
July 2014, Genzum successfully completes its Series B offering to private investors.
Genzum Initiates Bioequivalency Clinical Trial

June 2014, Genzum successfully initiates a global bioequivalency trial on a Ophthalmic ANDA product.
Genzum Establishes New Commercial Partnership
April 2014, Genzum establishes new commercial partnership for the development and out license of Genzum topical ANDA product with Tier 1 Pharmaceutical partner. Further details to be released.
Meet Genzum at DCAT Week 2014

March 2014, Waldorf Astoria Hotel, New York – To schedule a meeting, email us at: partnering@genzum.com.

Read more at: http://www.dcat.org/pages/week_DCATWeek.aspx 

Meet Genzum at AAPS Conference

11 – 13 November 2013, San Antonio, Texas – To schedule a meeting, email us at: partnering@genzum.com.

Read more at:  http://www.aaps.org/Meetings_and_Professional_Development/Calendar/2013/2013_AAPS_Annual_Meeting_and_Exposition/

Meet Genzum at CPhI Worldwide Conference

22 – 24 October 2013, Messe Frankfurt Germany – To schedule a meeting, email us at: partnering@genzum.com.

Read more at: http://www.cphi.com/europe/about/#sthash.ppI0qBAa.dpuf.

Genzum Initiates Phase III Clinical Trial
October 2013, Genzum successfully initiates a Phase III Clinical BA/BE trial on its Ophthalmic ANDA product.
Genzum Commercial Partnership
July 2013, Genzum establishes new collaboration and commercial partnership for the development and out license of topical ANDA products. Further details to be released.
Genzum Scientific Advisory Board
July 2013, Genzum Scientific Advisory Board signs partnership deal with a top-tier topical brand company at the annual American Academy of Dermatology meeting. More at: http://www.aad.org/meetings/2013-summer-meeting
Genzum Ophthalmic ANDA FDA Submission

June 17th, 2013 Genzum in collaboration with its commercial partner, successfully filed an ANDA application with the FDA. Further details to be released.
Genzum Private Capital Raise

June 2013, Genzum successfully completes its Series A offering to private investors.
Genzum Topical Pipeline

January 2013, Genzum adds two topical ANDA development projects to existing product development collaboration with a tier 1 generic distributor. Further details to be released.
Genzum Phase III Clinical Trial
December 2012, Genzum successfully completes a Phase III Clinical trial on its Ophthalmic ANDA product.
parallax layerparallax layer

CONTACT

9665 Wilshire Blvd,
Suite 430
Los Angeles CA 90212

E: info@genzum.com

T: (310) 299.8500

F: (310) 246.9987